{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Pregnancy Testing', 'WOCBP should only be included after a negative highly sensitive urine or serum pregnancy', 'test. If applicable, this test should be repeated a maximum of 24 hours before the first dose.', 'Following initiation of treatment, pregnancy testing will be performed at monthly intervals', 'during treatment and until the end of relevant systemic exposure to the study drug, in', 'accordance with the CTFG guidance on contraception.', 'Confidential', 'Page 77 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Appendix 4: Evaluation of radiologic images', 'CT AND MRI SCANS', 'CT is the best currently available and reproducible method to measure lesions selected for', 'response assessment. CT scans are recommended to have slice thickness of < 5 mm. MRI', 'is also acceptable.', 'If prior to enrollment it is known that a patient is unable to undergo CT scans with IV contrast', 'because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI', '(without IV contrast) will be used to evaluate the patient at baseline and during the study', 'should be guided by the tumor type under investigation and the anatomic location of the', 'disease. For patients who develop contraindications to contrast after baseline contrast CT is', 'done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be', 'performed should also be based on the tumor type and the anatomic location of the disease,', 'and should be optimized to allow for comparison with the prior studies if possible. Each case', 'should be discussed with the radiologist to determine if substitution of these other approaches', 'is possible. As the primary endpoint of the trial is based on detection of relapse/progression', 'of disease, different and changing modalities are permitted and unlikely to introduce bias.', 'ENDOSCOPY, LAPAROSCOPY, ULTRASOUND, CYTOLOGY, HISTOLOGY', 'Endoscopy, laparoscopy, ultrasound, cytology and histology if clinically indicated and', 'performed can be used to prove tumor relapse/progression. If relapse is proven/suspected by', 'ultrasound, confirmation by CT/MRI should in any case be obtained.', 'IDENTIFICATION OF RELAPSE OR PROGRESSION', 'The definite decision to diagnose a relapse/progression should be made by the investigator,', 'taking perspectives of the radiologist and/or the interdisciplinary tumor conference into', 'account - if applicable. Relapse/progression can be diagnosed by solid metastases in organs', 'like liver or lung or indirect signs (progressive ascites). In unclear cases, confirmation by', 'biopsy might be considered, if possible. As long as uncertainty concerning the remission', 'status must be stated, continuation of study therapy is recommended.', 'All potential new lesions should be evaluated as such. Measurements of all new lesions (or', 'local progression) and involved organs is required and should be reported in the eCRF.', 'Lymph nodes, particularly in local and timely connection to interventions, as site of relapse', 'may only be considered definite lesions if they present with a short diameter of 15 mm or', 'longer. All other relapses in lymph nodes require individual reporting and/or consultation with', 'the sponsor representative. The total number of involved organs should be determined and', 'also the total number of lesions (in case of more than 10 lesions, estimations are permitted)', 'NEW LESIONS', 'The appearance of new malignant lesions denotes disease progression/relapse; therefore,', 'some comments on detection of new lesions are important. There are no specific criteria for', 'the identification of new radiographic lesions; however, the finding of a new lesion should be', 'Confidential', 'Page 78 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'unequivocal, that especially not represent something other than active tumor. For example,', 'necrosis of a liver lesion may be reported on a CT scan report as a \"new\" cystic lesion, which', 'it is not.', 'If a new lesion is equivocal, for example because of its small size, continued therapy and', 'follow-up evaluation will clarify if it represents truly new disease. If repeated scans confirm', 'there is definitely a new lesion, progression should be declared using the date of the initial', 'scan.', 'Confidential', 'Page 79 of 79']\n\n###\n\n", "completion": "END"}